217 related articles for article (PubMed ID: 12832562)
21. Modulation of glutamate release and excitotoxicity by adenosine A2A receptors.
Popoli P; Frank C; Tebano MT; Potenza RL; Pintor A; Domenici MR; Nazzicone V; Pèzzola A; Reggio R
Neurology; 2003 Dec; 61(11 Suppl 6):S69-71. PubMed ID: 14663014
[TBL] [Abstract][Full Text] [Related]
22. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
Guyot MC; Hantraye P; Dolan R; Palfi S; Maziére M; Brouillet E
Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
[TBL] [Abstract][Full Text] [Related]
23. Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats.
Corsi C; Melani A; Bianchi L; Pedata F
Neuroreport; 2000 Aug; 11(11):2591-5. PubMed ID: 10943728
[TBL] [Abstract][Full Text] [Related]
24. Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging.
Ishiwata K; Ogi N; Hayakawa N; Oda K; Nagaoka T; Toyama H; Suzuki F; Endo K; Tanaka A; Senda M
Ann Nucl Med; 2002 Nov; 16(7):467-75. PubMed ID: 12508837
[TBL] [Abstract][Full Text] [Related]
25. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
26. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors.
Díaz-Cabiale Z; Vivó M; Del Arco A; O'Connor WT; Harte MK; Müller CE; Martínez E; Popoli P; Fuxe K; Ferré S
Neurosci Lett; 2002 May; 324(2):154-8. PubMed ID: 11988350
[TBL] [Abstract][Full Text] [Related]
27. Corticostriatopallidal neuroprotection by adenovirus-mediated ciliary neurotrophic factor gene transfer in a rat model of progressive striatal degeneration.
Mittoux V; Ouary S; Monville C; Lisovoski F; Poyot T; Conde F; Escartin C; Robichon R; Brouillet E; Peschanski M; Hantraye P
J Neurosci; 2002 Jun; 22(11):4478-86. PubMed ID: 12040055
[TBL] [Abstract][Full Text] [Related]
28. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage.
Fink JS; Kalda A; Ryu H; Stack EC; Schwarzschild MA; Chen JF; Ferrante RJ
J Neurochem; 2004 Feb; 88(3):538-44. PubMed ID: 14720203
[TBL] [Abstract][Full Text] [Related]
29. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease.
Blum D; Galas MC; Gall D; Cuvelier L; Schiffmann SN
Neurobiol Dis; 2002 Aug; 10(3):410-26. PubMed ID: 12270701
[TBL] [Abstract][Full Text] [Related]
30. Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats.
Corsi C; Melani A; Bianchi L; Pepeu G; Pedata F
Neuroreport; 1999 Mar; 10(4):687-91. PubMed ID: 10208531
[TBL] [Abstract][Full Text] [Related]
31. Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of Huntington's disease models.
Li W; Silva HB; Real J; Wang YM; Rial D; Li P; Payen MP; Zhou Y; Muller CE; Tomé AR; Cunha RA; Chen JF
Neurobiol Dis; 2015 Jul; 79():70-80. PubMed ID: 25892655
[TBL] [Abstract][Full Text] [Related]
32. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases.
Abbracchio MP; Cattabeni F
Ann N Y Acad Sci; 1999; 890():79-92. PubMed ID: 10668415
[TBL] [Abstract][Full Text] [Related]
33. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats.
Tariq M; Khan HA; Elfaki I; Al Deeb S; Al Moutaery K
Brain Res Bull; 2005 Sep; 67(1-2):161-8. PubMed ID: 16140176
[TBL] [Abstract][Full Text] [Related]
35. The role of striatal adenosine A2A receptors in regulation of the muscle tone in rats.
Wardas J; Konieczny J; Lorenc-Koci E
Neurosci Lett; 1999 Dec; 276(2):79-82. PubMed ID: 10624796
[TBL] [Abstract][Full Text] [Related]
36. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons.
Mori A; Shindou T; Ichimura M; Nonaka H; Kase H
J Neurosci; 1996 Jan; 16(2):605-11. PubMed ID: 8551344
[TBL] [Abstract][Full Text] [Related]
37. Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.
Sayed NH; Fathy N; Kortam MA; Rabie MA; Mohamed AF; Kamel AS
Neurotherapeutics; 2020 Jan; 17(1):252-268. PubMed ID: 31728850
[TBL] [Abstract][Full Text] [Related]
38. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease.
Nash JE; Brotchie JM
J Neurosci; 2000 Oct; 20(20):7782-9. PubMed ID: 11027242
[TBL] [Abstract][Full Text] [Related]
39. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum.
Rodrigues RJ; Alfaro TM; Rebola N; Oliveira CR; Cunha RA
J Neurochem; 2005 Feb; 92(3):433-41. PubMed ID: 15659214
[TBL] [Abstract][Full Text] [Related]
40. Evidence for high-affinity binding sites for the adenosine A2A receptor agonist [3H] CGS 21680 in the rat hippocampus and cerebral cortex that are different from striatal A2A receptors.
Cunha RA; Johansson B; Constantino MD; Sebastião AM; Fredholm BB
Naunyn Schmiedebergs Arch Pharmacol; 1996 Feb; 353(3):261-71. PubMed ID: 8692280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
